MS201924_0022 (DDRiver 322)

Listing Category

An Open label, Multicenter, Phase 1b/2a Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the ATR inhibitor M1774 in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies.

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Tracy Dobbs, Tennessee Cancer Specialists
Scroll to Top